Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Promising Outlook - US Cancer Vaccine Market
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Aug, 2018| No. of Pages : 150
Please make your selection :
Electronic Access - Single User License
US$ 1400.00
CD-ROM Mail Delivery
US$ 1600.00
Hard Copy Mail Delivery
US$ 1600.00
Electronic Access - Multi-User License
US$ 2000.00
List of Figures:
Figure 3-1: US - Cancer Incidences (Million), 2015 & 2025
Figure 3-2: US - Cancer Mortality (Million), 2015 & 2025
Figure 3-3: US - Incidences by Cancer Type (%), 2018
Figure 3-4: US - States with Highest Cancer Incidences (2018)
Figure 5-1: Global - Cancer Vaccine Market (Million US$), 2017-2023
Figure 5-2: US - Cancer Vaccine Market (Million US$), 2017-2023
Figure 5-3: Share of US in Global Cancer Vaccine Market (%), 2017
Figure 5-4: US - Cancer Vaccine Market by Product Type (%), 2017
Figure 5-5: US - Provenge Market (Million US$), 2013-2017
Figure 5-6: Share of US in Global Imlygic Sales (%), 2017
Figure 5-7: Global - Gardasil Market (Million US$), 2013-2017
Figure 5-8: US - Gardasil Market (Million US$), 2013-2017
Figure 5-9: Share of US in Global Gardasil Sales (%), 2017
Figure 5-10: Global - Cervarix Market (Million US$), 2013-2017
Figure 5-11: US - Cervarix Market (Million US$), 2013-2016
Figure 5-12: Share of US in Global Cervarix Sales (%), 2016
Figure 5-13: Global - Engerix-B & Twinrix Market (Million US$), 2013-2017
Figure 5-14: US - Engerix-B & Twinrix Market (Million US$), 2013-2017
Figure 5-15: Share of US in Global Engerix-B & Twinrix Sales (%), 2017
Figure 5-16: Global - Recombivax HB Market (Million US$), 2013-2017
Figure 5-17: US - Recombivax HB Market (Million US$), 2013-2017
Figure 5-18: Share of US in Global Recombivax HB Sales (%), 2017
Figure 5-19: Global - Pediarix/Infanrix Market (Million US$), 2013-2017
Figure 5-20: US - Pediarix/ Infanrix Market (Million US$), 2013-2017
Figure 5-21: Share of US in Global Pediarix/Infanrix Sales (%), 2017
Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2017
Figure 6 -2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2017-2023
Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2017-2023
Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2017-2023
Figure 7-1: US - Cancer Vaccine Market by Application (%), 2017
Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2017-2023
Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2017-2023
Figure 8-1: US - Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site
Figure 8-2: US - Prophylactic Cancer Vaccines in Clinical Trials by Phases
Figure 8-3: US - Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site
Figure 8-4: US - Therapeutic Cancer Vaccines in Clinical Trials by Phases
Figure 8-5: U S - Cancer Vaccines in Clinical Trials by Application
Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2017
Figure 12-1: Merck & Co., Inc. - Breakup of Sales by Business Segment (%), 2017
Figure 12-2: Merck & Co., Inc. - Breakup of Sales by Geography (%), 2017
Figure 12-3: GlaxoSmithKline - Breakup of Group Turnover by Business Segment (%), 2017
Figure 12-4: GlaxoSmithKline - Breakup of Group Turnover by Geography (%), 2017
Figure 12-5: Amgen Inc. - Breakup of Revenue by Geography (%), 2017
List of Tables:
Table 3-1: US - Top 10 Cancer Incidences in Males (2018)
Table 3-2: US - Top 10 Cancer Incidences in Females (2018)
Table 3-3: US - Top 10 Cancer Incidences in Children Age Group 0-14 Years (2018)
Table 4-1: US - Cancer Incidences (Million), 2015, 2020 & 2025
Table 8-1: Cancers with High Linkage to Virus and Bacteria
Table 8-2: US - Prophylactic Cancer Vaccines in Clinical Trials
Table 8-3: US - Therapeutic Cancer Vaccines in Clinical Trials
Table 8-4: US - Prostate Cancer Therapeutic Vaccines in Clinical Trials
Table 8-5: US - Breast Cancer Therapeutic Vaccines in Clinical Trials
Table 8-6: US - Lung Cancer Therapeutic Vaccines in Clinical Trials
Table 8-7: US - Colorectal Cancer Therapeutic Vaccines in Clinical Trials
Table 12-1: Merck & Co., Inc. - Key Financials (Million US$), 2015-2017
Table 12-2: Merck & Co., Inc. - Product Portfolio
Table 12-3: Merck & Co., Inc. - Cancer Vaccines in Pipeline
Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2015-2017
Table 12-5: GlaxoSmithKline - Product Portfolio
Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
Table 12-7: Dendreon Pharmaceuticals LLC - Product Portfolio
Table 12-8: Amgen Inc. - Key Financials (Million US$), 2015-2017
Table 12-9: Amgen Inc. - Product Portfolio
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact